# Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Source: https://onco.cc/trials/nct06238921/  
OnCo record `nct06238921` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of zimberelimab and sacituzumab govitecan in triple-negative breast cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.

## Summary

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases. ClinicalTrials.gov record last updated 2025-12-05: recruiting. Enrollment is planned at 31 participants. Primary completion is estimated at 2027-02. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan. Registered primary measures: Phase I: Neurologic Toxicity; Phase II: Progression Free Survival (PFS).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: TARGET-TNBC
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06238921
- Phase: 1/2
- Setting: Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
- Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Enrolled: 31

## Notes

- ClinicalTrials.gov record last updated 2025-12-05: recruiting. Enrollment is planned at 31 participants. Primary completion is estimated at 2027-02. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT06238921: https://clinicaltrials.gov/study/NCT06238921

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Zimberelimab](https://onco.cc/drugs/zimberelimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06238921.json